Scleroderma News and Research RSS Feed - Scleroderma News and Research

Scleroderma is a chronic, often progressive, autoimmune disease in which the body's immune system attacks its own body. The disease, which literally means "hard skin," can cause a thickening and tightening of the skin. In some cases it causes serious damage to internal organs including the lungs, heart, kidneys, esophagus and gastrointestinal tract. Some medicines and treatments can help with certain symptoms, but there is still no cure for scleroderma, which affects about 300,000 nationwide. (By way of comparison, about 50,000 people have muscular dystrophy, 250,000 are estimated to have lupus and 350,000 have multiple sclerosis.)
Autoimmune disease forum to be held in Tampa on March 28, 2015

Autoimmune disease forum to be held in Tampa on March 28, 2015

The "What Every American Needs to Know About Autoimmune Disease" public forum arrives in Tampa on Saturday, March 28th. The program will begin at 9:30am and end at 3:30pm. [More]
Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records

Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records

OpenText, the global leader in Enterprise Information Management (EIM), today announced that the Royal Free London NHS Foundation Trust has implemented OpenText Content Suite to store and manage digitised copies of patient medical care records. [More]
Researchers identify molecular pathways associated with distinct subsets of SSc patients

Researchers identify molecular pathways associated with distinct subsets of SSc patients

For years, doctors have been baffled about why some patients with systemic sclerosis (SSc) respond to therapy while others do not. [More]
Gene therapy transforms life for men with severe form of hemophilia B

Gene therapy transforms life for men with severe form of hemophilia B

Gene therapy developed at St. Jude Children's Research Hospital, University College London and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported. [More]
New potential therapeutic targets for treatment of pulmonary arterial hypertension

New potential therapeutic targets for treatment of pulmonary arterial hypertension

Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago. [More]
Researchers working to develop new drugs for treating chronic inflammatory diseases

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong. [More]
BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain. [More]
Dentists’ awareness can improve oral health of scleroderma patients

Dentists’ awareness can improve oral health of scleroderma patients

A survey of dentists in Massachusetts suggests that their confidence in treating patients with scleroderma may be related to their familiarity with the autoimmune disease. [More]
PAH risk factors identified for systemic sclerosis patients

PAH risk factors identified for systemic sclerosis patients

Researchers have identified clinical features that could help predict which patients with systemic sclerosis are likely to go on to develop pulmonary arterial hypertension (PAH) and therefore benefit most from early treatment. [More]
Northwestern Medicine study provides new insights on tissue scarring in scleroderma

Northwestern Medicine study provides new insights on tissue scarring in scleroderma

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma. [More]
Research provides new approach to developing better treatment options for scleroderma

Research provides new approach to developing better treatment options for scleroderma

Scleroderma is a rare and often fatal disease, causing the thickening of tissue, that currently lacks a cure and any effective treatments. A group of researchers, including a Michigan State University professor, is looking to change that. [More]
Royal Free London NHS Foundation Trust selects OpenText to manage scanned legacy case-notes

Royal Free London NHS Foundation Trust selects OpenText to manage scanned legacy case-notes

OpenText, the global leader in Enterprise Information Management (EIM), announced today that it has been selected by the Royal Free London NHS Foundation Trust to manage its scanned legacy case-notes. [More]
Scientists find origin of Leri's pleonosteosis in children and adults

Scientists find origin of Leri's pleonosteosis in children and adults

Scientists from The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have identified the cause of a rare condition called Leri's pleonosteosis. [More]
Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer. [More]
Cancer triggers scleroderma, shows evidence

Cancer triggers scleroderma, shows evidence

Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage. [More]
Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease. [More]
Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Women with chronic autoimmune diseases who take immunosuppressive medications during their first trimester of pregnancy are not putting their babies at significantly increased risk of adverse outcomes, according to a Vanderbilt study released online by the journal Arthritis and Rheumatism. [More]
National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

A National autoimmune disease multi-city conference tour arrives in Charleston, SC on Saturday, November 2, 2013. The conference "What Every American Needs to Know About Autoimmune Disease," is one of a series of free patient forums hosted by the American Autoimmune Related Diseases Association. [More]
Research points to causes, potential treatment approaches for systemic sclerosis

Research points to causes, potential treatment approaches for systemic sclerosis

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of systemic sclerosis, showing that a critical culprit is a defect in the way certain cells communicate with their structural scaffolding [More]
Key findings may have broad implications for future scleroderma therapy

Key findings may have broad implications for future scleroderma therapy

The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy. [More]
Advertisement
Advertisement